- Home
- NBY vs LIPO Comparison
NBY vs LIPO Comparison
Compare NBY & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- LIPO
- Stock Information
- Founded
- NBY 2000
- LIPO 2005
- Country
- NBY United States
- LIPO United States
- Employees
- NBY N/A
- LIPO N/A
- Industry
- NBY
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- LIPO Health Care
- Exchange
- NBY Nasdaq
- LIPO Nasdaq
- Market Cap
- NBY 3.4M
- LIPO 3.1M
- IPO Year
- NBY 2007
- LIPO 2022
- Fundamental
- Price
- NBY $0.58
- LIPO $2.65
- Analyst Decision
- NBY Strong Buy
- LIPO
- Analyst Count
- NBY 1
- LIPO 0
- Target Price
- NBY $0.85
- LIPO N/A
- AVG Volume (30 Days)
- NBY 67.8K
- LIPO 176.2K
- Earning Date
- NBY 05-08-2025
- LIPO 05-08-2025
- Dividend Yield
- NBY N/A
- LIPO N/A
- EPS Growth
- NBY N/A
- LIPO N/A
- EPS
- NBY N/A
- LIPO N/A
- Revenue
- NBY $9,781,000.00
- LIPO $536,357.00
- Revenue This Year
- NBY $23.91
- LIPO N/A
- Revenue Next Year
- NBY $32.05
- LIPO N/A
- P/E Ratio
- NBY N/A
- LIPO N/A
- Revenue Growth
- NBY N/A
- LIPO 19.29
- 52 Week Low
- NBY $0.36
- LIPO $1.97
- 52 Week High
- NBY $9.10
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- NBY 50.71
- LIPO 57.23
- Support Level
- NBY $0.56
- LIPO $2.25
- Resistance Level
- NBY $0.60
- LIPO $2.44
- Average True Range (ATR)
- NBY 0.04
- LIPO 0.22
- MACD
- NBY 0.01
- LIPO 0.04
- Stochastic Oscillator
- NBY 75.00
- LIPO 88.39
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.